Study provides new look at why rare cancer often evades treatments
Por um escritor misterioso
Last updated 15 março 2025

Researchers at Boston Medical Center and Dana-Farber Cancer Institute have conducted one of the first-ever analyses of neuroendocrine tumors (NETs) at single-cell resolution, unlocking new insights into this rare and often hard-to-treat cancer. The findings represent a tremendous leap forward in understanding why these tumors are largely resistant to immunotherapy and provide key insights that could lead to future treatments.

Squamous Cell Carcinoma (SCC) Symptoms, Stages, Risk Factors and Treatment

Precision therapy for RET-altered cancers with RET inhibitors: Trends in Cancer

How to Harness the Immune System to Treat Cancer - - Life Extension

Rare' cancers are common, so why the lack of research funding?, Health

The Lancet Commission on the future of care and clinical research in autism - The Lancet

Smart Nanomaterials in Cancer Theranostics: Challenges and Opportunities

Study Provides New Look at Why Rare Cancer Often Evades Treatments

Spatial transcriptomics—the next evolution of cancer drug discovery - 10x Genomics

Scientists Diagnose Dinosaur With Malignant Bone Cancer - Cancer Health

8 Lung Cancer Nursing Care Plans - Nurseslabs